follow us
disclaim warranti liabil
due number sourc inform servic acquisdata pti ltd servic obtain
inher hazard electron distribut may delay omiss inaccuraci inform
servic acquisdata pti ltd affili agent sale repres distributor licensor
warrant accuraci complet current merchant abil fit particular purpos
inform servic avail acquisdata pti ltd servic event acquisdata pti ltd
affili agent sale repres distributor licensor liabl license anyon els loss
injuri caus whole part conting beyond control procur compil interpret edit write
report deliv inform servic acquisdata pti ltd servic event acquisdata
pti ltd affili agent sale repres distributor licensor liabl license anyon els
decis made action taken license relianc upon inform servic consequenti
special similar damag even advis possibl damag license agre liabil
acquisdata pti ltd affili agent sale repres distributor licensor aris kind
legal claim whether contract tort otherwis way connect acquisdata pti ltd servic shall
exceed amount license paid use acquisdata pti ltd servic twelv month immedi
preced event give rise claim
merck gener profit growth
net sale increas driven double-digit growth healthcar life scienc
ebitda pre
forecast sale earn rais follow versum acquisit
merck lead scienc technolog compani gener strong organ sale growth benefit
posit foreign exchang effect third quarter ebitda pre increas even strongli net
sale three-month period juli septemb follow close versum materi versum
acquisit octob merck rais full-year forecast sale ebitda pre
third quarter continu resolut implement strategi substanti increas sale
earn thank strong perform healthcar life scienc well region success
acquisit versum begin octob perform materi achiev key mileston bright
futur transform program said stefan oschmann chairman execut board ceo merck
focus gener cash consequ rapidli lower debt ad marcu kuhnert member
execut board chief offic
group net sale rose million million group organ sale growth
fuel healthcar life scienc busi sector amount million currency-driven
sale increas million mainli due dollar japanes yen chines
ebitda pre group import earn indic increas million ebitda pre
margin improv develop ebitda pre reflect organ growth
posit exchang rate effect neg portfolio effect increas ebitda pre
pronounc sale attribut strong sale growth greater focu cost incom
allianc glaxosmithklin well continu margin improv healthcar life scienc
oper result ebit thu also increas million million
net incom profit tax attribut merck kgaa sharehold increas slightli million
million earn per share pre improv
net financi debt amount billion septemb around million less
end second quarter billion merck employe world-wide septemb
profit growth first nine month well
first nine month net sale increas million january-septemb
million period ebitda pre increas amount million january-
septemb million increas mainli organ ebitda pre margin rose one
percentag point january-septemb earn per share pre increas
third quarter healthcar busi sector increas sale million
million organ growth amount currency-rel increas strong busi
perform mainli due mavenclad well high demand medicin china
fertil medicin gonal-f diabet treatment glucophag oncolog drug erbitux
mavenclad oral treatment multipl sclerosi merck gener sale million third quarter
million increas comparison million mavenclad also
approv unit state march owe continu difficult competit situat interferon
market well competit oral dosag form rebif use treat multipl sclerosi saw double-
digit organ declin includ posit exchang rate effect sale amount million
million sale immuno-oncolog medicin bavencio increas million
million may bavencio approv unit state combin axitinib treatment
patient advanc renal cell carcinoma approv europ follow octob third quarter
sale oncolog drug erbitux increas organ million million
favor growth larg due addit erbitux nrdl nation reimburs drug list china
sale gonal-f lead recombin hormon treatment infertil increas million
million particular perform north america china contribut double-digit organ
ebitda pre healthcar soar million third quarter million
up-front payment allianc glaxosmithklin co-develop co-commerci
bifunct immunotherapi bintrafusp alfa posit effect around million
organ earn growth amount support posit exchang rate effect
life scienc see strongest contribut sale process
third quarter life scienc busi sector increas net sale million
year-earli quarter million reflect strong organ sale growth posit foreign
exchang effect neg portfolio effect divest cytometri
busi three busi unit region contribut organ growth earli octob merck acquir
flodesign sonic unit state uniqu acoust cell process platform industri
cell gene therapi manufactur
process solut busi unit market product servic entir pharmaceut product
valu chain gener organ sale growth highest rate within life scienc busi
sector assist favor foreign exchang effect net sale total million third quarter
million research solut busi unit provid product servic
support life scienc research pharmaceut biotechnolog academ research laboratori record
organ increas sale support posit foreign exchang effect net sale amount
million million broad rang product research well scientif industri
laboratori appli solut busi unit record strong organ sale growth third quarter
assist favor foreign exchang effect sale total million third quarter
million life scienc busi sector increas ebitda pre million
million double-digit growth primarili organ yet also support foreign
exchang effect portfolio effect
foreign exchang effect partli compens organ sale declin perform materi
third quarter sale perform materi busi sector decreas million
million first half display solut busi unit still notic benefit
liquid crystal busi individu custom capac expans project china third quarter
declin liquid crystal busi alreadi forecast previou year continu organ declin
partli off-set posit foreign exchang effect result mainli stronger dollar
comparison previou year well asian currenc thetaiwan dollar japanes yen
display solut busi unit consist mainli busi liquid crystal photoresist display
applic materi expect record organ declin third quarter
decreas partli off-set exchang rate effect consequ sale fell total
million million solut busi unit compris busi
materi use integr circuit product overal third quarter custom silicon wafer product
output remain expect backdrop continu weak semiconductor market
owe weak market condit sale declin organ howev off-set
posit exchang rate effect sale amount million million third quarter
net sale surfac solut busi unit declin organ includ posit foreign
exchang effect sale amount million million declin attribut
weaker demand particularli automot industri well increas portfolio focu industri
applic within scope bright futur transform program
ebitda pre perform materi decreas million million organ
ebitda pre declin foreign exchang effect partli compens
merck complet acquisit compani intermolecular septemb versum materi
octob acquisit strengthen perform materi consider expand compani
posit lead supplier electron materi semiconductor display industri versum
consolid calendar day yearend contribut sale ebitda pre
forecast rais follow acquisit versum
merck continu expect full year moder organ net sale increas previou
year fiscal merck expect portfolio effect versum acquisit around million group
overal net sale merck group forecast billion billion previous
billion billion billion merck continu expect strong organ increas ebitda
pre compar previou year contribut legaci versum busi ebitda pre forecast
around million million addit merck continu expect posit foreign exchang effect
compar group ebitda pre forecast overal corridor billion
billion previous billion billion billion
acquisdata proud host leagu estim want opportun win free
subscript join acquisdata media telecommun leagu
merck lead scienc technolog compani healthcar life scienc perform materi around
employe work develop technolog improv enhanc life biopharmaceut
therapi treat cancer multipl sclerosi cutting-edg system scientif research product liquid
crystal smartphon lcd televis
acquisdata date busi intellig report cover develop world
report vast archiv corpor document list compani around world
line basf se corpor purpos around employe contribut success custom
nearli sector almost everi countri world basf se broad portfolio rang chemic plastic
perform product crop protect product oil ga basf post sale billion
incom oper special item approxim billion combin econom success
environment protect social respons research innov basf se support
custom nearli everi industri meet current futur need societi basf se sum
contribut corpor purpos basf se creat chemistri sustain futur
grow age world popul requir adequ suppli food improv medic care bayer ag
research develop activ therefor focus improv peopl qualiti life prevent
allevi treat diseas time make import contribut provid reliabl
suppli high-qual food feed plant-bas raw materi bayer ag understand biochem
process live organ help address demand challeng
energi produc serv power econom growth lift peopl poverti futur way heat
light mobil deliv chang aim anchor busi chang pattern demand
rather quest suppli real contribut make world ambit low carbon
deutsch bauchemi top associ among manufactur construction-chem product
year form nation european-level interfac member compani polit author
construct industri standardis institut research teach deutsch bauchemi organis
made compani annual turnov billion euro compani achiev half
european market volum one third global market rang member compani deutsch
bauchemi reach small medium-s special supplier global player oper world-wide
member associ stand top-class product willing provid great servic
combin power scienc technolog passion innov essenti human progress
compani drive innov extract valu materi polym chemic biolog scienc help
address mani world challeng problem need fresh food safer sustain
transport clean water energi effici durabl infrastructur increas agricultur product
integr market-driven portfolio deliv broad rang technology-bas product solut high-
growth sector packag infrastructur transport consum care electron agricultur
evonik one world lead specialti chemic compani central element evonik strategi
sustain valu creation profit growth effici valu around percent sale come market-
lead posit systemat expand evonik concentr high-growth megatrend
especi health nutrit resourc effici global evonik employe
gener sale billion oper result adjust ebitda billion around percent
sale gener outsid germani provid convinc evid busi global
henkel oper global well-balanc diversifi portfolio compani hold lead posit
three busi unit industri consum busi thank strong brand across industri segment
world-wide laundri beauti busi henkel hold lead posit mani
market categori around world found henkel look back year success
henkel employ peopl global passion highli divers team unit strong
compani cultur common purpos creat sustain valu share valu recogn leader
sustain henkel hold top posit mani intern indic rank henkel prefer share
list german stock index dax
lyondellbasel nyse one world largest plastic chemic refin compani member
 lyondellbasel manufactur product site countri lyondellbasel product
technolog use make item improv qualiti life peopl around world includ packag
electron automot part home furnish construct materi biofuel
lanxess lead specialti chemic compani sale eur billion
employe countri compani current repres product site world-wide core
busi lanxess develop manufactur market chemic intermedi specialti
chemic plastic arlanxeo joint ventur saudi aramco lanxess also lead
supplier synthet rubber lanxess list lead sustain indic jone sustain index
djsi world
lind group world lead supplier industri process special gase one
profit engin compani product servic found nearli everi industri
countri success stori began separ air
growth gloom spread german chemic industri
germani power chemic industri feder tuesday slash outlook say slow
european economi threat afield would drag perform
mood sector recent cloud significantli said utz tillmann director feder
industri germani europ downturn import client industri throttl product includ
vital car sector still hobbl tough new emiss test introduc septemb tillmann said
vci forecast fall product slip revenu billion euro
last quarterli updat decemb vci forecast modest growth percent lift
product percent higher sale
repres germani third-largest industri sector vci gather around firm rang giant
multin like basf tini famili compani togeth employ peopl
mani chemic maker stand upstream manufactur confront slew challeng
within eurozon singl currenc bloc heavyweight economi itali recess amid fear public debt
outsid britain brink disorderli exit european union later month washington trade
conflict brussel beij roll china growth slow markedli
mani threat german european economi far new alreadi prove drag
chemic product sale
vci report output volum rose percent last year sale grew percent billion euro
much increas one-off effect product new blockbust drug vci said
product fall percent pharmaceut rule
littl reason celebr tillmann said
background expect weak year chemic
acquisdata date busi intellig report cover develop world
report vast archiv corpor document list compani around world
